naltrexone/bupropion
AssetAlso NB32, Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Naltrexone SR 32 mg/bupropion SR 360 mg/ day
Combination dopamine/norepinephrine reuptake inhibitor and opioid antagonist suppressing appetite.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- SLC6A2
- 7
- Indications
- 219
- Trials
- 1
- Developer
Indications
7Cardiovascular disease
Phase 3, Terminated, NCT02638129, clinicaltrials.gov, 8 Oct 2026
Obesity
Phase 3, Terminated, NCT02638129, clinicaltrials.gov, 8 Oct 2026
Overweight
Phase 3, Completed, NCT00567255, clinicaltrials.gov, 7 Oct 2026
4 more
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials219
- Evidence for its targets4
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.